Watson presents safety data on silodosin

The USA's Watson Pharmaceuticals presented efficacy and safety data on Rapaflo (silodosin), its investigational treatment for benign prostatic hyperplasia, at two regional meetings of the American Urological Association.

The results of three Phase III studies showed that treatment with Rapaflo for up to one year effectively reduces the symptoms of BPH and is well tolerated without causing any significant changes in blood pressure or adverse cardiac effects. Cardiac safety data further demonstrated that Rapaflo, alone or in combination with medications for erectile dysfunction, showed only minimal effects on blood pressure or heart rate.

"We are excited by these clinical data as they further support the strong and sustained efficacy, as well as the safety and tolerability of Rapaflo that have been demonstrated in other trials," said Edward Heimers president of Watson's Brand Division.